Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Christensen

Showing results (401-410 of 510) with videos related to

Pageof 51
Sort By:
Oncogene|February 2, 2010
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorD Ercan, K Zejnullahu, K Yonesaka, et al.
Acta Oncologica (Stockholm, Sweden)|January 31, 2019
MyHealth: specialist nurse-led follow-up in breast cancer. A randomized controlled trial - development and feasibilityLena Saltbæk, Randi V Karlsen, Pernille E Bidstrup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET InhibitionThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Molecular Cancer Therapeutics|July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinibOndrej Kalous, Dylan Conklin, Amrita J Desai, et al.
European Journal of Clinical Investigation|May 31, 2001
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failureH G Eiken, E Øie, J K Damås, et al.
Genes, Chromosomes & Cancer|August 19, 2008
Expression and mutational analysis of MET in human solid cancersPatrick C Ma, Maria S Tretiakova, Alexander C MacKinnon, et al.
The British Journal of Nutrition|December 1, 2022
Rationale and design of IMPACT-women: a randomised controlled trial of the effect of time-restricted eating, healthy eating and reduced sedentary behaviour on metabolic health during chemotherapy for early-stage breast cancerRebecca A G Christensen, Mark J Haykowsky, Michelle Nadler, et al.
Scientific Reports|May 22, 2021
The TGF-β ligand DBL-1 is a key player in a multifaceted probiotic protection against MRSA in C. elegansMaria G M Mørch, Katrine V Møller, Marianne O Hesselager, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Cancer Discovery|May 16, 2012
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsBarbara Sennino, Toshina Ishiguro-Oonuma, Ying Wei, et al.
Pageof 51

Showing results (401-410 of 510) with videos related to

Sort By:
Pageof 51
Oncogene|February 2, 2010
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorD Ercan, K Zejnullahu, K Yonesaka, et al.
Acta Oncologica (Stockholm, Sweden)|January 31, 2019
MyHealth: specialist nurse-led follow-up in breast cancer. A randomized controlled trial - development and feasibilityLena Saltbæk, Randi V Karlsen, Pernille E Bidstrup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET InhibitionThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Molecular Cancer Therapeutics|July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinibOndrej Kalous, Dylan Conklin, Amrita J Desai, et al.
European Journal of Clinical Investigation|May 31, 2001
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failureH G Eiken, E Øie, J K Damås, et al.
Genes, Chromosomes & Cancer|August 19, 2008
Expression and mutational analysis of MET in human solid cancersPatrick C Ma, Maria S Tretiakova, Alexander C MacKinnon, et al.
The British Journal of Nutrition|December 1, 2022
Rationale and design of IMPACT-women: a randomised controlled trial of the effect of time-restricted eating, healthy eating and reduced sedentary behaviour on metabolic health during chemotherapy for early-stage breast cancerRebecca A G Christensen, Mark J Haykowsky, Michelle Nadler, et al.
Scientific Reports|May 22, 2021
The TGF-β ligand DBL-1 is a key player in a multifaceted probiotic protection against MRSA in C. elegansMaria G M Mørch, Katrine V Møller, Marianne O Hesselager, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Cancer Discovery|May 16, 2012
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsBarbara Sennino, Toshina Ishiguro-Oonuma, Ying Wei, et al.
Pageof 51